Impact of pneumococcal conjugate vaccines on nasopharyngeal carriage and invasive disease among unvaccinated people: review of evidence on indirect effects (Q38107709)

From Wikidata

Jump to navigation Jump to search

scientific article published on 16 May 2013

Language	Label	Description	Also known as
English	Impact of pneumococcal conjugate vaccines on nasopharyngeal carriage and invasive disease among unvaccinated people: review of evidence on indirect effects	scientific article published on 16 May 2013

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

29 August 2017

0 references

Impact of pneumococcal conjugate vaccines on nasopharyngeal carriage and invasive disease among unvaccinated people: review of evidence on indirect effects (English)

1 reference

Europe PubMed Central

PubMed publication ID

29 August 2017

invasive disease

1 reference

based on heuristic

inferred from title

object named as

Katherine L O'Brien

4

0 references

Maria Deloria Knoll

2

object named as

Maria Deloria-Knoll

1 reference

Europe PubMed Central

PubMed publication ID

29 August 2017

author name string

Stephanie M Davis

1

1 reference

Europe PubMed Central

PubMed publication ID

29 August 2017

Hilina T Kassa

3

1 reference

Europe PubMed Central

PubMed publication ID

29 August 2017

language of work or name

0 references

publication date

16 May 2013

1 reference

Europe PubMed Central

PubMed publication ID

29 August 2017

1 reference

Europe PubMed Central

PubMed publication ID

29 August 2017

32

1 reference

Europe PubMed Central

PubMed publication ID

29 August 2017

1

1 reference

Europe PubMed Central

PubMed publication ID

29 August 2017

133-145

1 reference

Europe PubMed Central

PubMed publication ID

29 August 2017

Aging population and future burden of pneumococcal pneumonia in the United States

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.05.005

7 January 2021

The preventable burden of pneumococcal disease in the developing world

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.05.005

7 January 2021

Which pneumococcal serogroups cause the most invasive disease: implications for conjugate vaccine formulation and use, part I.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.05.005

7 January 2021

Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Northern California Kaiser Permanente Vaccine Study Center Group

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.05.005

7 January 2021

Efficacy and safety of seven-valent conjugate pneumococcal vaccine in American Indian children: group randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.05.005

7 January 2021

Geographic variation in invasive pneumococcal disease following pneumococcal conjugate vaccine introduction in the United States

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.05.005

7 January 2021

Impact of pneumococcal conjugate vaccination of infants on pneumonia and influenza hospitalization and mortality in all age groups in the United States

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.05.005

7 January 2021

Effect of Pneumococcal Conjugate Vaccine on Nasopharyngeal Colonization among Immunized and Unimmunized Children in a Community‐Randomized Trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.05.005

7 January 2021

Serum serotype-specific pneumococcal anticapsular immunoglobulin g concentrations after immunization with a 9-valent conjugate pneumococcal vaccine correlate with nasopharyngeal acquisition of pneumococcus

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.05.005

7 January 2021

The fundamental link between pneumococcal carriage and disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.05.005

7 January 2021

Indirect effects associated with widespread vaccination of infants with heptavalent pneumococcal conjugate vaccine (PCV7; Prevnar).

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.05.005

7 January 2021

Standards for CHERG reviews of intervention effects on child survival

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.05.005

7 January 2021

Impact of pneumococcal conjugate vaccine and the severity of winter influenza-like illnesses on invasive pneumococcal infections in children and adults

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.05.005

7 January 2021

Changing epidemiology of pneumococcal meningitis after the introduction of pneumococcal conjugate vaccine in the United States

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.05.005

7 January 2021

Trends in Invasive Pneumococcal Disease—Associated Hospitalizations

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.05.005

7 January 2021

Declining incidence of nonbacteremic pneumococcal pneumonia [corrected] in hospitalized elderly patients at a tertiary care hospital after the introduction of pneumococcal vaccines in Taiwan, 2004 to 2008

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.05.005

7 January 2021

Vaccination of day-care center attendees reduces carriage of Streptococcus pneumoniae among their younger siblings

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.05.005

7 January 2021

Nasopharyngeal carriage of Streptococcus pneumoniae in Gambian children who participated in a 9-valent pneumococcal conjugate vaccine trial and in their younger siblings.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.05.005

7 January 2021

Changes in pneumococcal serotypes and antibiotypes carried by vaccinated and unvaccinated day-care centre attendees in Portugal, a country with widespread use of the seven-valent pneumococcal conjugate vaccine.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.05.005

7 January 2021

Invasive pneumococcal disease in Portugal prior to and after the introduction of pneumococcal heptavalent conjugate vaccine.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.05.005

7 January 2021

Post-PCV7 changes in colonizing pneumococcal serotypes in 16 Massachusetts communities, 2001 and 2004.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.05.005

7 January 2021

Invasive Pneumococcal Disease a Decade after Pneumococcal Conjugate Vaccine Use in an American Indian Population at High Risk for Disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.05.005

7 January 2021

Emergence of Invasive Pneumococcal Disease Caused by Nonvaccine Serotypes in the Era of 7-Valent Conjugate Vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.05.005

7 January 2021

Trends in mortality and antibiotic resistance among HIV-infected patients with invasive pneumococcal disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.05.005

7 January 2021

Invasive Streptococcus pneumoniae infections in children and older adults in the north of Spain before and after the introduction of the heptavalent pneumococcal conjugate vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.05.005

7 January 2021

Changes in Streptococcus pneumoniae serotypes causing invasive disease with non-universal vaccination coverage of the seven-valent conjugate vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.05.005

7 January 2021

Has the licensing of respiratory quinolones for adults and the 7-valent pneumococcal conjugate vaccine (PCV-7) for children had herd effects with respect to antimicrobial non-susceptibility in invasive Streptococcus pneumoniae?

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.05.005

7 January 2021

Impact of more than a decade of pneumococcal conjugate vaccine use on carriage and invasive potential in Native American communities

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.05.005

7 January 2021

Changes in nasopharyngeal carriage and serotype distribution of antibiotic-resistant Streptococcus pneumoniae before and after the introduction of 7-valent pneumococcal conjugate vaccine in Hong Kong

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.05.005

7 January 2021

Carriage of Streptococcus pneumoniae 3 years after start of vaccination program, the Netherlands

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.05.005

7 January 2021

Pneumococcal disease in South Australia: vaccine success but no time for complacency

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.05.005

7 January 2021

Bacterial meningitis in the United States, 1998-2007.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.05.005

7 January 2021

The epidemiology of invasive pneumococcal disease in British Columbia following implementation of an infant immunization program: increases in herd immunity and replacement disease.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.05.005

7 January 2021

Eradication of invasive pneumococcal disease due to the seven-valent pneumococcal conjugate vaccine serotypes in Calgary, Alberta.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.05.005

7 January 2021

Herd immunity and serotype replacement 4 years after seven-valent pneumococcal conjugate vaccination in England and Wales: an observational cohort study

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.05.005

7 January 2021

Four years of universal pneumococcal conjugate infant vaccination in Germany: Impact on incidence of invasive pneumococcal disease and serotype distribution in children

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.05.005

7 January 2021

Impact of pneumococcal vaccination in Denmark during the first 3 years after PCV introduction in the childhood immunization programme

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.05.005

7 January 2021

Impact of universal pneumococcal vaccination on hospitalizations for pneumonia and meningitis in children in Montevideo, Uruguay.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.05.005

7 January 2021

The epidemiology of community acquired bacteremic pneumonia, due to Streptococcus pneumoniae, in the Top End of the Northern Territory, Australia--over 22 years

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.05.005

7 January 2021

Impact of heptavalent pneumococcal conjugate vaccine on invasive disease, antimicrobial resistance and colonization in Alaska Natives: progress towards elimination of a health disparity

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.05.005

7 January 2021

Invasive pneumococcal disease caused by nonvaccine serotypes among alaska native children with high levels of 7-valent pneumococcal conjugate vaccine coverage

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.05.005

7 January 2021

Indirect effect of conjugate vaccine on adult carriage of Streptococcus pneumoniae: an explanation of trends in invasive pneumococcal disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.05.005

7 January 2021

Epidemiology of pneumococcal meningitis hospitalizations in pediatric population in Spain (1998-2006).

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.05.005

7 January 2021

Serotypes and antimicrobial susceptibilities of invasive Streptococcus pneumoniae pre- and post-seven valent pneumococcal conjugate vaccine introduction in Alberta, Canada, 2000-2006

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.05.005

7 January 2021

Decrease of invasive pneumococcal infections in children among 8 children's hospitals in the United States after the introduction of the 7-valent pneumococcal conjugate vaccine.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.05.005

7 January 2021

Decline in pneumococcal meningitis after the introduction of the heptavalent-pneumococcal conjugate vaccine in northern France

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.05.005

7 January 2021

Serotype replacement in disease after pneumococcal vaccination

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.05.005

7 January 2021

Decline in pneumonia admissions after routine childhood immunisation with pneumococcal conjugate vaccine in the USA: a time-series analysis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.05.005

7 January 2021

Invasive pneumococcal disease in non‐Indigenous people in north Queensland, 2001–2009

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.05.005

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/J.VACCINE.2013.05.005

1 reference

Europe PubMed Central

PubMed publication ID

29 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

29 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38107709&oldid=2128393850"